Form 4: scPharmaceuticals Director Minnie Baylor-Henry Receives 30,000 Stock Options

Minnie Baylor-Henry, a Director at scPharmaceuticals Inc., was granted 30,000 stock options with an exercise price of $3.85, vesting by June 2026 or the next annual meeting.

Summary

• Minnie Baylor-Henry, a Director of scPharmaceuticals Inc. (SCPH), was granted 30,000 stock options on June 3, 2025.
• The stock options have an exercise price of $3.85 per share.
• These options will vest in full upon the earlier of June 3, 2026, or the date of the Issuer's next annual meeting of stockholders.
• The options have an expiration date of June 3, 2035.
• Following this transaction, Ms. Baylor-Henry directly beneficially owns 30,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it represents a standard and expected form of equity compensation for a director, aligning their interests with shareholders. It does not indicate any negative operational or financial news for the company.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Negatives

• The value of the options is contingent on the future performance of scPharmaceuticals' stock price exceeding the exercise price of $3.85.
• There is no immediate cash inflow to the director from this grant.

Risks

• The value of the stock options is subject to market risk; if the company's stock price does not rise above the exercise price, the options may expire worthless.
• The vesting schedule means the options are not immediately exercisable and require continued service or the passage of time.

Future Outlook

The grant of these stock options provides a future incentive for the director, with potential value realization dependent on the company's stock performance over the next decade, specifically if the stock price exceeds the $3.85 exercise price.

Industry Context

The granting of stock options to non-employee directors is a common and widely accepted practice in the biotechnology and pharmaceutical industries, as well as across public companies generally. It serves as a key component of director compensation, aiming to align their long-term interests with those of the company's shareholders.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, including those in the pharmaceutical sector like scPharmaceuticals Inc.
• While the specific number of options and exercise price vary by company size, compensation philosophy, and individual director roles, this type of equity award is consistent with typical compensation structures for independent directors at comparable small to mid-cap biotech firms.

Stakeholder Impact

• Shareholders: The grant represents a minor potential future dilution if the options are exercised, but it also serves to align the director's interests with shareholder value creation.
• Director (Minnie Baylor-Henry): Receives a significant equity incentive, providing a direct financial interest in the company's stock performance.

Next Steps

• The stock options will vest in full upon the earlier of June 3, 2026, or the next annual meeting of scPharmaceuticals' stockholders.
• Upon vesting, the director will have the right to exercise these options at $3.85 per share until their expiration on June 3, 2035.

Key Dates

Keywords

scPharmaceuticals, SCPH, Stock Option, Director Grant, Insider Transaction, Form 4, Equity Compensation, Minnie Baylor-Henry